ReviewOncology research2026
Research on the Mechanism of "Cold Tumor" Formation and Immunotherapy for Its Transformation into "Hot Tumor".
Review in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A clear goal in cold tumor research is to identify strategies for converting them into immunologically 'hot' tumors with enhanced immune cell infiltration and activity, thereby improving their responsiveness to immunotherapy. The genesis of cold tumors is exceedingly intricate. In recent times, as the analysis of this phenomenon has been pursued with greater depth, a suite of advanced diagnostic and therapeutic technologies has surfaced. These novel approaches and tactics are anticipated to modulate the tumor immune microenvironment across various dimensions, thereby facilitating the advancement of personalized and precise treatment modalities for cold tumors. The present article addresses the challenge of diminished therapeutic responsiveness to "cold tumors" within clinical settings. It systematically elucidates the multi-faceted regulatory mechanisms underlying immune evasion in cold tumors and offers a detailed analysis of advanced therapeutic strategies that incorporate nanotechnology, gene editing, and artificial intelligence methodologies. Furthermore, the future development trends of immunotherapy were explored in greater depth. It was posited that the convergence of artificial intelligence, multidimensional genomics, and emerging biotechnologies has presented positive prospects for the treatment of cold tumors, and has offered a theoretical foundation and technical framework for the transformation of cold tumors into "hot tumors".
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.